Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News AstraZeneca ADR Representing 0.5 Ord Shs AZN

Consumer Cyclical Healthcare Advertising Agencies
AstraZeneca PLC is a science-led biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza... see more

Recent & Breaking News (NDAQ:AZN)

LYNPARZA® (Olaparib) Approved in the US for HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer

Business Wire May 20, 2020

ENHERTU Granted Breakthrough Therapy Designation in the US for HER2-Mutant Metastatic Non-Small Cell Lung Cancer

Business Wire May 18, 2020

AstraZeneca Advances the Science of Cancer Medicine With Practice-Changing Data at the ASCO20 Virtual Scientific Program

Business Wire May 13, 2020

Innate Pharma First Quarter 2020 Report

GlobeNewswire May 12, 2020

Myriad Receives FDA Approval of myChoice CDx® as Companion Diagnostic for Lynparza(TM) (olaparib) In Patients with Advanced Ovarian Cancer

GlobeNewswire May 11, 2020

ENHERTU Granted Breakthrough Therapy Designation in the US for HER2-Positive Metastatic Gastric Cancer

Business Wire May 11, 2020

LYNPARZA (Olaparib) Approved in US as 1st-line Maintenance Treatment With bevacizumab For HRD-Positive Advanced Ovarian Cancer

Business Wire May 11, 2020

FARXIGA Approved in the US for the Treatment of Heart Failure in Patients With Heart Failure With Reduced Ejection Fraction

Business Wire May 6, 2020

LOKELMA US Label Updated to Include Dosing Guidance for the Treatment of Hyperkalemia in Patients With End-Stage Renal Disease on Hemodialysis

Business Wire April 27, 2020

LYNPARZA® (Olaparib) Demonstrated Overall Survival Benefit in Phase III PROfound Trial for BRCA1/2 or ATM-Mutated Metastatic Castration-Resistant Prostate Cancer

Business Wire April 24, 2020

KOSELUGO(TM) (selumetinib) Approved In US For Pediatric Patients With Neurofibromatosis Type 1 Plexiform Neurofibromas

Business Wire April 13, 2020

RedHill Biopharma Completes Acquisition of Movantik® from AstraZeneca

GlobeNewswire April 2, 2020

BRILINTA reduced bleeding vs dual therapy in high-risk coronary patients in sub-analyses from Phase IV TWILIGHT trial

Business Wire March 30, 2020

FARXIGA Phase III DAPA-CKD Trial Will Be Stopped Early After Overwhelming Efficacy in Patients With Chronic Kidney Disease

Business Wire March 30, 2020

IMFINZI (durvalumab) Approved in the US for Extensive-Stage Small Cell Lung Cancer

Business Wire March 30, 2020

FARXIGA reduced the incidence of heart failure worsening or cardiovascular death in a sub-analysis from landmark Phase III DAPA-HF trial

Business Wire March 28, 2020

First Patient Dosed in IPH5201 Phase I Clinical Trial in Advanced Solid Tumors

GlobeNewswire March 10, 2020

RedHill Biopharma Provides Full-Year 2019 Financial Results and Operational Highlights

GlobeNewswire March 4, 2020

RedHill Biopharma Acquires Rights to Movantik® from AstraZeneca

GlobeNewswire February 25, 2020

NeoTX Closes $45 Million Series C Financing

GlobeNewswire February 19, 2020